Evaluation of antioxidant and immunity function of tetramethylpyrazine phosphate tablets in Vivo

Molecules

Volumn 17, Issue 5, 2012, Pages 5412-5421

  Guo, Ling ^a   Wang, Aihong ^a   Sun, Yongle ^a   Xu, Chongen ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

GSH Px; LVEDP; LVSP; Tetramethylpyrazine phosphate tablets

Indexed keywords

ANTIOXIDANT; CARDIOTONIC AGENT; CATALASE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; ISOPRENALINE; MALONALDEHYDE; ORGANOPHOSPHATE; PYRAZINE DERIVATIVE; SUPEROXIDE DISMUTASE; TETRAMETHYLPYRAZINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; IMMUNOLOGY; METABOLISM; ORGAN SIZE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; TABLET; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; BODY WEIGHT; CARDIOTONIC AGENTS; CATALASE; GLUTATHIONE PEROXIDASE; HEART; HEART FAILURE; INTERLEUKIN-6; ISOPROTERENOL; MALONDIALDEHYDE; ORGAN SIZE; OXIDATIVE STRESS; PHOSPHORIC ACID ESTERS; PYRAZINES; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TABLETS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 84861515066     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17055412     Document Type: Article

References (56)

1. Fang, J.; Mensah, G.A.; Croft, J.B.; Keenan, N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J. Am. Coll. Cardiol. 2008, 52, 428-434.
2. Parissis, J.T.; Fountoulaki, K.; Paraskevaidis, I.; Kremastinos, D. Depression in chronic heart failure: Novel pathophysiological mechanisms and therapeutic approaches. Expert Opin. Investig. Drugs 2005, 14, 567-577.
3. Schäfer, A.; Fraccarollo, D.; Werner, L.; Bauersachs, J. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol. Res. 2010, 62, 432-438.
4. Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J. Card. Fail. 2010, 16, 475-539.
5. Dhalla, A.K.; Singal, P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 1994, 266, H1280-H1285.
6. Hill, M.F.; Singal, P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol. 1996, 148, 291-300.
7. Li, R.K.; Sole, M.J.; Mickle, D.A.G.; Schimmer, J.; Goldstein, D. Vitamin E and oxidative stress in the heart of the cardiomyopathic syrian hamster. Free Radic. Biol. Med. 1998, 24, 252-258.
8. Freeman, L.M.; Brown, D.J.; Rush, J.E. Assessment of degree of oxidative stress and antioxidant concentrations in dogs with idiopathic dilated cardiomyopathy. J. Am. Vet. Med. Assoc. 1999, 215, 644-646.
9. de Blois, J.; Simard, S.; Atar, D.; Agewall, S. For the norwegian heart failure registry. COPD predicts mortality in HF: The norwegian heart failure registry. J. Card. Fail. 2010, 16, 225-229.
10. Jewett, S.L.; Eddy, L.J.; Hochstein, P. Is the autoxidation of catecholamine involved in ischemia-reperfusion injury? Free Radic. Biol. Med. 1989, 6, 185-188.
11. Byrne, J.A.; Grieve, D.J.; Cave, A.C.; Shah, A.M. Oxidative stress and heart failure. Arch. Mal. Coeur Vaiss. 2003, 96, 214-221.
12. Giordano, F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 2005, 115, 500-508.
13. Heymes, C.; Bendall, J.K.; Ratajczak, P.; Cave, A.C.; Samuel, J.L.; Hasenfuss, G.; Shah, A.M. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 2003, 41, 2164-2171.
14. Li, J.M.; Gall, N.P.; Grieve, D.J.; Chen, M.; Shah, A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40, 477-484.
15. Stefan, D.; Anker, S.D.; Haehling, S.V. Inflammatory mediators in chronic heart failure: An overview. Heart 2004, 90, 464-470.
16. Chang, Y.; Hsiao, G.; Chen, S.H.; Chen, Y.C.; Lin, J.H.; Lin, K.H.; Chou, D.S.; Sheu, J.R. Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol. Sin. 2007, 28, 327-333.
17. Luo, X.X.; Ogata, H.; Xu, X.; Ishitobi, F. Protective effect of tetramethylpyrazine on ischemic neuronal damage in the gerbil hippocampus. No To Shinkei 1994, 46, 841-846.
18. Kerckhoven, R.V.; van Veen, T.A.B.; Boomsma, F.; Saxena, P.R.; Schoemaker, R.G. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur. J. Pharmacol. 2000, 397, 113-120.
19. Liao, S.L.; Kao, T.K.; Chen, W.Y.; Lin, Y.S.; Chen, S.Y.; Raung, S.L.; Wu, C.W.; Lu, H.C.; Chen, C.J. Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci. Lett. 2004, 30, 40-45.
20. Feng, M.G.; Feng, G.H.; Zhou, Q.G. Effects ofmethylhesperidin on coronary, renal and cerebral circulation in dogs (in Chinese). Acta Pharmacol. Sin. 1988, 9, 548-550.
21. Dai, X.Z.; Bache, R.J. Coronary and systemic haemodynamic effect of tetramethylpyrazine in the dog. J. Cardiovasc. Pharmacol. 1985, 7, 841-849.
22. Tuttle, R.S.; Marmelstein, L.; Trad, T.; Reddy, S.; Radley, T. In vitro uterine response to tetramethylpyrazine, the active constituent of chung chong (a traditional Chinese medicine). Am. J. Obstet. Gynecol. 1989, 161, 1319-1323.
23. Salem, R.; Denault, A.Y.; Couture, P.; Bélisle, S.; Fortier, A.; Guertin, M.-C.; Carrier, M.; Martineau, R. Left ventricular end-diastolic pressure is a predictor of mortality in cardiac surgery independently of left ventricular ejection fraction. Br. J. Anaesth. 2006, 97, 292-297.
24. Hohensinner, P.J.; Niessner, A.; Huber, K.; Weyand, C.M.; Wojta, J. Inflammation and cardiac outcome. Curr. Opin. Infect. Dis. 2011, 24, 259-264.
25. Diwan, A.; Tran, T.; Misra, A.; Mann, D.L. Inflammatory mediators and the failing heart: A translational approach. Curr. Mol. Med. 2003, 3, 161-182.
26. Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J.B.; Mann, D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996, 27, 1201-1206.
27. Deswal, A.; Petersen, N.J.; Feldman, A.M.; Young, J.B.; White, B.G.; Mann, D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103, 2055-2059.
28. Dixon, D.-L.; Griggs, K.M.; Bersten, A.D.; de Pasquale, C.G. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 2011, 56, 593-599.
29. Hori, M.; Nishida, K. Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovasc. Res. 2009, 81, 457-464.
30. Kleinbongard, P.; Heusch, G.; Schulz, R. TNFa in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 2010, 127, 295-314.
31. Tappe, K.H.; Mohammadzadeh, H.; Khashaveh, S.; Rezapour, B.; Barazesh, A. Prevalence of intestinal parasitic infections among primary school attending students in Barandooz-Chay rural region of Urmia, West Azerbaijan province, Iran in 2008. Afr. J. Microbiol. Res. 2011, 5, 788-791.
32. Noor, N.A. Anxiolytic action and safety of Kava: Effect on rat brain acetylcholinesterase activity and some serum biochemical parameters. Afr. J. Pharm. Pharmacol. 2010, 4, 823-828.
33. Sun, M.; Chen, M.; Dawood, F.; Zurawska, U.; Li, J.Y.; Parker, T.; Kassiri, Z.; Kirshenbaum, L.A.; Arnold, M.; Khokha, R.; et al. Tumor necrosis factor-alpha mediates Cardia cre modeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115, 1398-4071.
34. Shaw, S.M.; Shah, M.K.; Williams, S.G.; Fildes, J.E. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur. J. Heart Fail. 2009, 11, 113-118.
35. Dhalla, A.K.; Singal, P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 1994, 266, H1280-H1285.
36. Hill, M.F.; Singal, P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol. 1996, 148, 291-300.
37. Li, R.K.; Sole, M.J.; Mickle, D.A.G.; Schimmer, J.; Goldstein, D. Vitamin E and oxidative stress in the heart of the cardiomyopathic syrian hamster. Free Radic. Biol. Med. 1998, 24, 252-258.
38. Freeman, L.M.; Brown, D.J.; Rush, J.E. Assessment of degree of oxidative stress and antioxidant concentrations in dogs with idiopathic dilated cardiomyopathy. J. Am. Vet. Med. Assoc. 1999, 215, 644-646.
39. Polidori, M.C.; Stahl, W.; Eichler, O.; Niestroj, N.; Sies, H. Profiles of antioxidants in human plasma. Free Radic. Biol. Med. 2001, 30, 456-462.
40. Marin-Garcia, J.; Goldenthal, M.J.; Moe, G.W. Mitochondrial pathology in cardiac failure. Cardiovasc. Res. 2001, 49, 17-26.
41. Sawyer, D.B.; Colucci, W.S. Mitochondrial oxidative stress in heart failure. "Oxygen wastage" revisited. Circ. Res. 2000, 86, 119-120.
42. Gey, K.F.; Moser, U.K.; Jordan, P.; Stähelin, H.B.; Eichholzer, M.; Ludin, E. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: An epidemiological update with special attention to carotene and vitamin C. Am. J. Clin. Nutr. 1998, 57, 787S-797S.
43. Hughes, C.M.; Woodside, J.V.; McGartland, C.; Roberts, M.J.; Nicholls, D.P.; McKeown, P.P. Nutritional intake and oxidative stress in chronic heart failure. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 376-382.
44. Olivetti, G.; Abbi, R.; Quaini, F.; Kajstura, J.; Cheng, W.; Nitahara, J.A.; Quaini, E.; Di Loreto, C.; Beltrami, C.A.; Krajewski, S.; et al. Apoptosis in the failing human heart. N. Engl. J. Med. 1997, 336, 1131-1141.
45. Jethwani Urmi, N.; Mulla Summaiya, A.; Shah Latika, N. Detection of inducible clindamycin resistance by an automated system in a tertiary care hospital. Afr. J. Microbiol. Res. 2011, 5, 2870-2872.
46. Dhalla, A.K.; Hill, M.F.; Singal, P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol. 1996, 28, 506-514.
47. Singal, P.K.; Dhalla, A.K.; Hill, M.; Thomas, T.P. Endogenous antioxidant changes in the myocardium in response to acute and chronic stress conditions. Mol. Cell. Biochem. 1993, 129, 179-186.
48. Lai, C.C.; Peng, M.; Huang, L.; Huang, W.H.; Chiu, T.H. Chronic exposure of neonatal cardiac myocytes to hydrogen peroxide enhances the expression of catalase. J. Mol. Cell. Cardiol. 1996, 28, 1157-1163.
49. Sedigheh, A.; Jamal, M.S.; Mahbubeh, S.; Somayeh, K.; Mahmoud, R.-K.; Azadeh, A.; Fatemeh, S. Hypoglycaemic and hypolipidemic effects of pumpkin (Cucurbita pepo L.) on alloxan-induced diabetic rats. Afr. J. Pharm. Pharmacol. 2011, 5, 2620-2626.
50. Dieterich, S.; Bieligk, U.; Beulich, K.; Hasenfuss, G.; Prestle, J. Gene expression of antioxidative enzymes in the human heart: Increased expression of catalase in the end-stage failing heart. Circulation 2000, 101, 33-39.
51. Buege, J.A.; Aust, S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52, 302-310.
52. Ellman, G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82, 70-77.
53. Misra, H.P.; Fridovich, I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247, 3170-3175.
54. Chiu, D.T.Y.; Stults, F.H.; Tappel, A.L. Purification and properties of rat lung soluble glutathione peroxidase. Biochim. Biophys. Acta 1976, 445, 558-566.
55. Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105, 121-127.
56. Luna, L.C. Manual of Histological Screening Methods of Armed Forces Institute of Pathology; McGraw Hill Book Co.: New York, NY, USA, 1960.